Interferon-lambda 1 polypeptides
View Patent ↗A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.
1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
the amino acid sequence of the full-length interferon-λ1 (IFN-λ1) polypeptide having the complete amino acid sequence of SEQ ID NO:8;
amino acids 2-200 of SEQ ID NO:8; and
amino acids 23-200 of SEQ ID NO:8.
2. A composition comprising an interferon-λ1 (IFN-λ1) polypeptide and a pharmaceutically acceptable carrier, wherein said IFN-λ1 polypeptide comprises:
the complete amino acid sequence of SEQ ID NO:8;
amino acids 2-200 of SEQ ID NO:8; or
amino acids 23-200 of SEQ ID NO:8.